Who are etanercept or adalimumab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CYCLOSPORINE VS INFLIXIMAB, Infliximab-Dyyb, Certolizumab Pegol (CZP), Adalimumab, etanercept, infliximab, Adalimumab with methotrexate, TDM-based infliximab intravenous therapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/etanercept-or-adalimumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

etanercept or adalimumab — Competitive Intelligence Brief

etanercept or adalimumab (etanercept or adalimumab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-alpha inhibitor. Area: Immunology.

marketed TNF-alpha inhibitor TNF-alpha (tumor necrosis factor-alpha) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

etanercept or adalimumab (etanercept or adalimumab) — University of Glasgow. TNF-alpha inhibitors that block tumor necrosis factor-alpha signaling to reduce inflammation in autoimmune and inflammatory diseases.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
etanercept or adalimumab TARGET	etanercept or adalimumab	University of Glasgow	marketed	TNF-alpha inhibitor	TNF-alpha (tumor necrosis factor-alpha)
CYCLOSPORINE VS INFLIXIMAB	CYCLOSPORINE VS INFLIXIMAB	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	marketed	Immunosuppressant (cyclosporine); TNF-alpha inhibitor (infliximab)	Calcineurin (cyclosporine); TNF-alpha (infliximab)
Infliximab-Dyyb	Infliximab-Dyyb	Asan Medical Center	marketed	TNF-alpha inhibitor; monoclonal antibody	TNF-alpha (TNFα)
Certolizumab Pegol (CZP)	Certolizumab Pegol (CZP)	UCB Pharma	marketed	TNF-alpha inhibitor	TNF-alpha
Adalimumab, etanercept, infliximab	Adalimumab, etanercept, infliximab	University of Padova	marketed	TNF-alpha inhibitor	TNF-alpha (tumor necrosis factor-alpha)
Adalimumab with methotrexate	Adalimumab with methotrexate	Pfizer	marketed	TNF-alpha inhibitor + DMARD combination	TNF-alpha; dihydrofolate reductase
TDM-based infliximab intravenous therapy	TDM-based infliximab intravenous therapy	Asan Medical Center	marketed	TNF-alpha inhibitor	TNF-alpha (Tumor Necrosis Factor-alpha)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-alpha inhibitor class)

Abbott · 4 drugs in this class
Centre for Human Drug Research, Netherlands · 2 drugs in this class
Samsung Bioepis Co., Ltd. · 2 drugs in this class
Alvotech Swiss AG · 2 drugs in this class
UCB Pharma · 2 drugs in this class
Celltrion · 2 drugs in this class
AbbVie (prior sponsor, Abbott) · 2 drugs in this class
Assistance Publique Hopitaux De Marseille · 1 drug in this class
Asan Medical Center · 1 drug in this class
Carmel Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). etanercept or adalimumab — Competitive Intelligence Brief. https://druglandscape.com/ci/etanercept-or-adalimumab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab